Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators.
Article
Overview
publication date
- October 1, 2008
published in
- European urology Journal
Identity
Scopus Document Identifier
- 58249093739
PubMed ID
- 18953756
Additional Document Info
has global citation frequency
volume
- 54
issue
- 4